Tag Archive for ‘neoadjuvant therapy’
Three important trials examining adjuvant therapies for biliary tract cancers, which were recently completed and reported, are summarized.
This month’s column provides an update on the ALCHEMIST trials for patients with operable lung cancer, including the addition of a third arm to study, which permits the inclusion of patients without ALK or EGFR mutations.
This month’s column summarizes the ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) platform and how it facilities definitive studies of adjuvant targeted therapies in biomarker-selected non-small cell lung cancer patients.
The rationale for neoadjuvant therapy is explored in this month’s column along with a summary of Alliance clinical trials involving this treatment.